Fairvalue-Calculator Fairvalue-Calculator
EN DE

PetVivo Holdings (PETV) Fair Value & Analysis

Healthcare · US · Market cap $29.3M

Price$0.8250
Fair Value$0.5200
Upside-37.0%
Quality95/100
Evidence: Low Range $0.3900 – $0.6500

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

PetVivo Holdings (PETV) currently trades at $0.8250, while our model-based Fair Value estimate is $0.5200 — implying the stock looks roughly 37.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

PetVivo Holdings, Inc., a biomedical device company, manufactures, commercializes, and licenses medical devices and therapeutics for animals in the United States. The company's lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. It also provides therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. is headquartered in Edina, Minnesota.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -23% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -81% Edwards Lifesciences Corporation (EW) -53% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is PetVivo Holdings (PETV) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $0.5200 versus a price of $0.8250 — about −37% (overvalued). Model-based estimate, not financial advice.
What is the fair value of PETV?
Our 21-model fair value for PetVivo Holdings is $0.5200 (as of Jun 24, 2026), built from audited fundamentals. The current price is $0.8250.
What is the quality score of PETV?
PetVivo Holdings has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.